

Jobkeeper s323DB(1) notice

Melbourne, Australia; 11 November 2021: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) provides the attached Jobkeeper Payments Notification in accordance with subsection 323DB(1) of the *Corporations Act 2001 (Cth)*.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP[®] drug delivery and VivaGel[®]. Starpharma has developed VIRALEZE[™], an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE[™] is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel[®] condom and VivaGel[®] BV. VivaGel[®] BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP[®], is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP[®] versions of existing drugs, particularly in the area of anti-cancer therapies. DEP[®] partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

Starpharma.com | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

Media: Sumit Media

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Jobkeeper Payments Notification

*A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001-
jobkeeper payments disclosure by listed entity.*

Date of this notice

11/11/2021

Listed entity details

Australian Business Number (ABN)

20078532180

ASX/NSX/SSX issuer code

SPL

Name of the listed entity

Starpharma Holdings Limited

Jobkeeper payments

This notice relates to the financial years ended 30/06/2020 (FY 1) and 30/06/2021 (FY 2).

The number of individuals for whom the listed entity or a subsidiary of the listed entity received a jobkeeper payment for a jobkeeper fortnight that ended in the financial year (within the meaning of the Coronavirus Economic Response Package (Payments and Benefits) Rules 2020).

FY 1: 41

FY 2: 42

The sum of all jobkeeper payments the listed entity, and each subsidiary of the listed entity, received in a jobkeeper fortnight that ended in the financial year.

FY 1: \$241,500

FY 2: \$534,000

Has the listed entity or a subsidiary of the listed entity, made one or more voluntary payments (whether or not in the financial year) to the Commonwealth by way of a repayment of jobkeeper payments received by the listed entity or a subsidiary of the listed in the financial year?

NO

If the listed entity or a subsidiary of the listed entity has made such a voluntary payment or payments -the sum of those payments:

FY 1:\$0

FY 2:\$0